{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:03:43Z","timestamp":1792785823494,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Alexion Pharmaceuticals and Mayo Clinic\u2019s Centre MS and Autoimmune Neurology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1093\/brain\/awz054","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T16:25:17Z","timestamp":1551889517000},"page":"1310-1323","source":"Crossref","is-referenced-by-count":207,"title":["Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders"],"prefix":"10.1093","volume":"142","author":[{"given":"Jacqueline","family":"Palace","sequence":"first","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Yu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of North Carolina, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglin","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of North Carolina, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Majed","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, Minnesota, USA"},{"name":"Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liene","family":"Elsone","sequence":"additional","affiliation":[{"name":"The Walton Centre, NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahd","family":"Hamid","sequence":"additional","affiliation":[{"name":"The Walton Centre, NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Messina","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Misu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Sagen","sequence":"additional","affiliation":[{"name":"Clinical Research Unit, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Whittam","sequence":"additional","affiliation":[{"name":"The Walton Centre, NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Takai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabel","family":"Leite","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Weinshenker","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Cabre","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fort-de-France University Hospital Center, Pierre Zobda Quitman Hospital, Fort-de-France, Martinique, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Jacob","sequence":"additional","affiliation":[{"name":"The Walton Centre, NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan"},{"name":"Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for NeuroScience, Koriyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J","family":"Pittock","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, Minnesota, USA"},{"name":"Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,1]]},"reference":[{"key":"2019042904533299600_awz054-B1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/1352458511421185","article-title":"Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy","volume":"18","author":"Barnett","year":"2012","journal-title":"Mult Scler"},{"key":"2019042904533299600_awz054-B2","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"2019042904533299600_awz054-B3","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1177\/1352458513515085","article-title":"Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset","volume":"20","author":"Collongues","year":"2014","journal-title":"Mult Scler"},{"key":"2019042904533299600_awz054-B4","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.0b013e3181d31e35","article-title":"Neuromyelitis optica in France: a multicenter study of 125 patients","volume":"74","author":"Collongues","year":"2010","journal-title":"Neurology"},{"key":"2019042904533299600_awz054-B5","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1212\/WNL.0b013e3181f39a66","article-title":"Long-term follow-up of neuromyelitis optica with a pediatric onset","volume":"75","author":"Collongues","year":"2010","journal-title":"Neurology"},{"key":"2019042904533299600_awz054-B6","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.msard.2015.07.017","article-title":"Placebo controlled trials in neuromyelitis optica are needed and ethical","volume":"4","author":"Cree","year":"2015","journal-title":"Mult Scler Relat Disord"},{"key":"2019042904533299600_awz054-B7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1472-6947-7-11","article-title":"Prognosis of the individual course of disease\u2013steps in developing a decision support tool for Multiple Sclerosis","volume":"7","author":"Daumer","year":"2007","journal-title":"BMC Med Inform Decis Making"},{"key":"2019042904533299600_awz054-B8","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann Neurol"},{"key":"2019042904533299600_awz054-B9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflamm"},{"key":"2019042904533299600_awz054-B10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458515587752","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints","volume":"22","author":"Jeong","year":"2016","journal-title":"Mult Scler"},{"key":"2019042904533299600_awz054-B11","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"key":"2019042904533299600_awz054-B12","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ophtha.2018.03.041","article-title":"Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis","volume":"125","author":"Jitprapaikulsan","year":"2018","journal-title":"Ophthalmology"},{"key":"2019042904533299600_awz054-B13","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1001\/jamaneurol.2018.0805","article-title":"Novel glial targets and recurrent longitudinally extensive transverse myelitis","volume":"75","author":"Jitprapaikulsan","year":"2018","journal-title":"JAMA Neurol"},{"key":"2019042904533299600_awz054-B14","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"2019042904533299600_awz054-B15","doi-asserted-by":"crossref","first-page":"e82325","DOI":"10.1371\/journal.pone.0082325","article-title":"Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS One"},{"key":"2019042904533299600_awz054-B16","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp-2013-306541","article-title":"Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials","volume":"85","author":"Kitley","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Pt 6","key":"2019042904533299600_awz054-B17","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"2019042904533299600_awz054-B18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"key":"2019042904533299600_awz054-B19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"key":"2019042904533299600_awz054-B20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"2019042904533299600_awz054-B21","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"2019042904533299600_awz054-B22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fneur.2017.00062","article-title":"Different Phenotypes at Onset in Neuromyelitis Optica Spectrum Disorder Patients with Aquaporin-4 Autoimmunity","volume":"8","author":"Long","year":"2017","journal-title":"Front Neurol"},{"key":"2019042904533299600_awz054-B23","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"key":"2019042904533299600_awz054-B24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler"},{"key":"2019042904533299600_awz054-B25","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J Neurol"},{"key":"2019042904533299600_awz054-B26","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/1352458506070732","article-title":"Immunosuppressive therapy is more effective than interferon in neuromyelitis optica","volume":"13","author":"Papeix","year":"2007","journal-title":"Mult Scler"},{"key":"2019042904533299600_awz054-B27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-017-0984-5","article-title":"Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination","volume":"14","author":"Peschl","year":"2017","journal-title":"J Neuroinflammation"},{"key":"2019042904533299600_awz054-B28","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/archneurol.2012.249","article-title":"Effects of age and sex on aquaporin-4 autoimmunity","volume":"69","author":"Quek","year":"2012","journal-title":"Arch Neurol"},{"key":"2019042904533299600_awz054-B29","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1177\/1352458516685416","article-title":"Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea","volume":"23","author":"Seok","year":"2017","journal-title":"Mult Scler"},{"key":"2019042904533299600_awz054-B30","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","article-title":"IFNbeta-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum","volume":"75","author":"Shimizu","year":"2010","journal-title":"Neurology"},{"key":"2019042904533299600_awz054-B31","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","article-title":"Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response","volume":"88","author":"Stellmann","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2019042904533299600_awz054-B32","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1468-1331.2009.02897.x","article-title":"Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis","volume":"17","author":"Uzawa","year":"2010","journal-title":"Eur J Neurol"},{"key":"2019042904533299600_awz054-B33","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2019042904533299600_awz054-B35","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1212\/WNL.0000000000001520","article-title":"Challenges and opportunities in designing clinical trials for neuromyelitis optica","volume":"84","author":"Weinshenker","year":"2015","journal-title":"Neurology"},{"key":"2019042904533299600_awz054-B36","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ana.20770","article-title":"Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis","volume":"59","author":"Weinshenker","year":"2006","journal-title":"Ann Neurol"},{"key":"2019042904533299600_awz054-B37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"2019042904533299600_awz054-B38","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/brain\/article-pdf\/142\/5\/1310\/28538281\/awz054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T04:55:54Z","timestamp":1556513754000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/142\/5\/1310\/5425266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,4,1]]},"published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awz054","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2019,4,1]]}}}